PDS Biotechnology Corporation(简称PDS Biotech)近日公布,其已对三期临床试验Versatile-003的研究方案作出重要修订。新版方案将无进展生存期(PFS)设定为中期分析的主要终点指标,这一调整旨在为后续可能的加速审批提供关键数据支撑。
PDS Biotechnology Corporation(简称PDS Biotech)近日公布,其已对三期临床试验Versatile-003的研究方案作出重要修订。新版方案将无进展生存期(PFS)设定为中期分析的主要终点指标,这一调整旨在为后续可能的加速审批提供关键数据支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.